Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HCT
NCT00089011Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Apr 2004
- Primary completion
- Mar 2014
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 2, open-label trial of fludarabine in hematologic malignancy (2 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Incidence of Grade III/IV Graft-versus-Host Disease at Day 180 and Incidence of Chronic Extensive Graft-versus-Host Disease at Day 180. Started Apr 2004; status: completed.
02
Drugs
fludarabine
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT00089011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089011.